Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Pluri Inc PLUR

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It ...


NDAQ:PLUR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by lucaM1on Apr 17, 2022 10:53am
164 Views
Post# 34608343

A New Cultured Meat report

A New Cultured Meat report

A New Cultured Meat report was released by visualcapitalist.com. 

The report, in part, talks about the big financial potential of this up-and-coming industry: "Depending on factors such as strong consumer demand, price parity, and innovation in cellular agriculture, the cultured meat market could explode within the next decade and be worth $25 billion by 2030 according to McKinsey.

Interestingly, the success of the cultured meat market will also bleed into other adjacent industries such as dairy, eggs, seafood, chocolate, and honey."

Companies like Pluristem (NASDAQ:$PSTI) who are establishing themselves as a leading player in the early stages of the industry could see amazing growth in the upcoming years. 

<< Previous
Bullboard Posts
Next >>